Dinaciclib: trials, targets and approvals

Trials 18

today NCT03484520 · Ph 1 NCT01676753 · Ph 1 NCT02684617 · Ph 1 NCT01783171 · Ph 1 NCT01711528 · Ph 1 NCT01650727 · Ph 1 NCT01624441 · Ph 1 NCT01580228 · Ph 3 NCT01515176 · Ph 1/2 NCT01434316 · Ph 1 NCT01026324 · Ph 1/2 NCT01096342 · Ph 2 NCT00937937 · Ph 2 NCT00871546 · Ph 2 NCT00798213 · Ph 2 NCT00732810 · Ph 2 NCT00871910 · Ph 1 NCT00871663 · Ph 1

200720082009201020112012201320142015201620172018201920202021202220232024202520262027

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 110 trials
Phase 1	NCT03484520	Jul 2018 → Dec 2022	acute myeloid leukemia	AbbVie	Terminated	No outcome recorded Stop: Business
Phase 1	NCT01676753	Dec 2016 → Jun 2020	triple-negative breast carcinoma	Jo Chien	Completed	No outcome recorded
Phase 1	NCT02684617	Mar 2016 → Apr 2020	B-cell chronic lymphocytic leukemia, diffuse large B-cell lymphoma	Merck Sharp & Dohme LLC	Terminated	No outcome recorded Stop: Business
Phase 1	NCT01783171	Jan 2013 → Jul 2016	pancreatic adenocarcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01711528	Dec 2012 → Nov 2016	plasma cell myeloma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01650727	Oct 2012 → Oct 2013	chronic lymphocytic leukemia/small lymphocytic lymphoma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT01624441	Aug 2012 → Sep 2013	male breast carcinoma, triple-negative breast carcinoma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1	NCT01434316	Nov 2011 → Mar 2023 overdue	cancer	National Cancer Institute (NCI)	Active not recruiting	No outcome recorded
Phase 1	NCT00871910	Oct 2006 → Feb 2010	non-Hodgkin lymphoma, plasma cell myeloma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1	NCT00871663	Aug 2006 → Oct 2012	B-cell chronic lymphocytic leukemia, plasma cell myeloma	Merck Sharp & Dohme LLC	Completed	No outcome recorded
Phase 1/22 trials
Phase 1/2	NCT01515176	Jan 2012 → Mar 2015	chronic lymphocytic leukemia/small lymphocytic lymphoma, prolymphocytic leukemia	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 1/2	NCT01026324	Sep 2009 → Oct 2014	melanoma	National Cancer Institute (NCI)	Terminated	No outcome recorded Stop: Enrollment
Phase 25 trials · 1 met primary · 1 missed
Phase 2	NCT00937937	Jul 2009 → Oct 2013 overdue	acral lentiginous melanoma, lentigo maligna melanoma, mucosal melanoma, nodular malignant melanoma	National Cancer Institute (NCI)	Active not recruiting	Met primary
Phase 2	NCT01096342	Jul 2009 → Dec 2011	plasma cell myeloma	National Cancer Institute (NCI)	Completed	No outcome recorded
Phase 2	NCT00871546	Mar 2009 → Dec 2010	B-cell chronic lymphocytic leukemia, mantle cell lymphoma	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 2	NCT00798213	Jan 2009 → Apr 2010	acute lymphoblastic leukemia, acute myeloid leukemia	Merck Sharp & Dohme LLC	Terminated	No outcome recorded
Phase 2	NCT00732810	Jul 2008 → Jun 2011	breast neoplasm, non-small cell lung carcinoma	Merck Sharp & Dohme LLC	Completed	Missed primary
Phase 31 trial
Phase 3	NCT01580228	Aug 2012 → Dec 2014	B-cell chronic lymphocytic leukemia	Merck Sharp & Dohme LLC	Completed	No outcome recorded

Press releases naming this drug 1 release

Date	Issuer	Release
2010-12-03	Ligand Pharmaceuticals	Ligand Announces Presentation of Data from Multiple Studies of Dinaciclib by its Partner Merck at the ASH Annual Meeting ligand.com ↗

Evidence & citations 9 cited values

Every value below carries the sentence it was read from. 20 sources stand behind the page.

Field	Value	Cited text
Known as	dinaciclib	“Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclin-dependent kinases, has been shown to induce apoptosis in preclinical studies of human...” PMID 24388167 ↗ Dec 2013 14 “Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.” PMID 23949430 ↗ Aug 2013 NCT02684617 ↗ NCT01026324 ↗ NCT01580228 ↗ NCT01783171 ↗ NCT03484520 ↗ NCT01434316 ↗ NCT01624441 ↗ NCT01676753 ↗ NCT01096342 ↗ Show 4 more sources
Known as	MK-7965	“Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclin-dependent kinases, has been shown to induce apoptosis in preclinical studies of human...” PMID 24388167 ↗ Dec 2013 1 “the CDK inhibitor dinaciclib (SCH727965; MK-7965)” PMID 25931518 ↗ Apr 2015
Known as	NSC 727135	“Southwest Oncology Group S0826: A phase 2 trial of SCH 727965 (NSC 727135, dinaciclib) in patients with stage IV melanoma.” PMID 39342463 ↗ Sep 2024
Known as	SCH727965	“Dinaciclib (MK-7965, formerly SCH 727965), a novel, small-molecule inhibitor of cyclin-dependent kinases, has been shown to induce apoptosis in preclinical studies of human...” PMID 24388167 ↗ Dec 2013 5 “Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias.” PMID 23949430 ↗ Aug 2013 “the CDK inhibitor dinaciclib (SCH727965; MK-7965)” PMID 25931518 ↗ Apr 2015 NCT00871910 ↗ NCT00871546 ↗ NCT00871663 ↗
Action	Inhibit	“inhibitor of cyclin-dependent kinases” PMID 24388167 ↗ Dec 2013
Modality	Small molecule	“a novel, small-molecule inhibitor of cyclin-dependent kinases” PMID 24388167 ↗ Dec 2013
Route	Intravenous	“administered IV” PMID 24388167 ↗ Dec 2013
Target	CDK2	“cdk2, combined cdk2/1 and cdk9 inhibition” NCT01026324 ↗
Target	CDK9	“cdk2, combined cdk2/1 and cdk9 inhibition” NCT01026324 ↗